Cyclophosphamide for Treatment of Refractory Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review and Meta-analysis.

Abstract

PURPOSE:

This study evaluates the tolerability and efficacy of cyclophosphamide (CYC) for the treatment of refractory chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).

METHODS:

We searched PubMed, Embase, Cochrane Library, and 2 Chinese databases (Chinese National Knowledge Infrastructure and SinoMed) for studies published between database inception and September 30, 2021. Articles obtained using the appropriate keywords were independently selected by 2 reviewers on the basis of the established inclusion and exclusion criteria.

FINDINGS:

In total, 240 records that were eventually curtailed to 13 studies with 83 patients were retrieved and subsequently included in this evaluation. All 13 studies were included in the systematic review, 7 of which were included in the meta-analysis. The pooled estimate of the response rate was 68% (95% CI, 45%-90%). The pooled estimate of the adverse reaction rate was 8% (95% CI, 0%-15%). The disease duration before the first CYC treatment was negatively correlated with the reduction in the modified Rankin Scale score (r = -0.76, P < 0.001). However, the response rates did not differ significantly between patients of different sexes (P = 0.716) or between patients who received and those who did not receive concurrent glucocorticoids (P = 0.617).

IMPLICATIONS:

CYC might be a recommended therapeutic option for patients with refractory CIDP, especially those who are unable to accept rituximab treatment. Earlier CYC treatment yields better therapeutic outcomes in patients with refractory CIDP without CYC-related contraindications.

• Authors: Qilang Xiang, Yuzi Cao, Zhuoyao Song, Huini Chen, Ziyi Hu, Shifeng Zhou, Yan Zhang, Hongxu Cui, Jie Luo, Yiying Qiang, Ye Wang, Shiquan Shuai, Yuan Yang, Min Yang, Xin Wei, Anji Xiong
• Journal: Clinical therapeutics (Clin Ther) Vol. 44 Issue 8 Pg. 1058-1070 (08 2022) ISSN: 1879-114X [Electronic] United States
• PMID: 35872028 (Publication Type: Journal Article, Meta-Analysis, Systematic Review, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2022 Elsevier Inc. All rights reserved.

Chemical References

• Glucocorticoids
• Immunoglobulins, Intravenous
• Rituximab
• Cyclophosphamide

Topics

• Cyclophosphamide (adverse effects)
• Glucocorticoids (therapeutic use)
• Humans
• Immunoglobulins, Intravenous
• Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (diagnosis, drug therapy)
• Rituximab (therapeutic use)